Orlistat in the treatment of obesity

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 4, 2000, Pages 841-847

  Ballinger, Anne ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Diabetes mellitus; Hyperlipidaemia; Hypertension; Obesity, orlistat, weight loss

Indexed keywords

ANTIOBESITY AGENT; LACTONE; TETRAHYDROLIPSTATIN;

CLINICAL TRIAL; DRUG INTERACTION; HUMAN; OBESITY; REVIEW;

ANTI-OBESITY AGENTS; CLINICAL TRIALS; DRUG INTERACTIONS; HUMANS; LACTONES; OBESITY;

EID: 0034189683     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.4.841     Document Type: Article

References (19)

1. PI-SUNYER FX: Medical hazards of obesity. Ann. Intent. Med.(1993) 119:655-660. • In depth review of the complications of obesity.
2. WATERLOW JC: Research on obesity: a report of a DHSS/MRC Group. Department of Health, HMSO, London, UK (1976).
3. BOST L, PRIMATESTA P, DONC W: Antropometric measures and children's iron status. In: Health Survey for England '96. Department of Health, HMSO, London, UK (1998).
4. THE NATIONAL HEART, LUNG AND BLOOD INSTITUTE EXPERT PANEL ON THE IDENTIFICATION, EVALUATION AND TREATMENT OF OVERWEIGHT AND OBESITY IN ADULTS: Executive summary of the clinical guidelines on the identification, evaluation and treatment of overweight and obesity adults. Arch. Intern. Med. (1998) 158:1178-1191.
5. GOLDSTEIN DJ: Beneficial health effects of modest weight loss. Int.J. Obes. (1992) 6:397-415. • Obese patients who lose only 5% of initial body weight show improvement in cardiovascular risk factors and co-existing disorders.
6. LUQUE CA, REY JA: Sibutramine: a serotoninnorepinephrine reuptake-inhibitor for the treatment of obesity. Ann. Pbarmacother. (1999) 33(9):968-978.
7. KELLY SM, SHORTHOUSE M, COTTERELL JE et al.: A 3 month double-blind controlled trial of feeding with sucose polyester in human volunteers. Br. J. Kutr. (1998) 80(0:41-49.
8. HEYMSFIELD SB, GREENBERG AS, FUJIOKA K et al.: Recombinant leptin for weight loss in obese and lean adults: a randomized controlled, dose-escalation trial. JAMA (1999) 282(16):1568-1575. • Mean weight loss at 6 months was 7.1 kg with the highest dose of leptin.
9. ZHI J, MULLIGAN TE, HAUPTMAN JB: Long-term systemic exposure of orlistat, a lipase inhibitor and its metabolites in obese patients./ Clin. Pharmacol. (1999) 39(1):4M6. • Detection of intact orlistat in plasma was sporadic and measurable concentrations were low without evidence of accumulation, which is consistent with minimal absorption.
10. Hoffrnan-La Roche. Data sheet.
11. GUERCIOLINI R: Mode of action of orlistat. Int. J. Obes. (1997) 21(Suppl. 3):S12-S23.
12. VAN GAAL LF, BROOM JI, ENZI G, TOPLAK H: The Orlistat Dose-Ranging Group. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur. J. Clin. Pbarmacol. (1998) 54:125-132.
13. SJOSTROM L, RISSANEN A, ANDERSEN T et al: Randomised placebo-controlled triai of orlistat for weight loss and prevention of regain in obese patients. Lancet (1998) 352:167-173. •• 2-year treatment with orlistat plus diet significantly promotes weight loss, lessens weight regain and improves some obesity-related disease risk factors.
14. DAVIDSON MH, HAUPTMAN J, DIGIROLAMO M et al: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. A randomized controlled trial JAMA (1999) 281:235-242. •• 2-year treatment with orlistat plus diet significantly promotes weight loss, lessens weight regain and improves some obesity-related disease risk factors.
15. ROSSNER S, SJOSTROM L, NOACK R, MEINDERS AE, NOSEDA G: Weight loss, weight maintenance and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes. Res. (2000) 8:49-61. •• Orlistat administered for 2 years promotes weight loss and minimises weight regain. Additionally, orlistat therapy improves lipid profile, blood pressure and quality of life.
16. HILL JO, HAUPTMAN J, ANDERSON JW et al: Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-year study. Am. J. Clin. Nutr. (1999) 69:1108-1116.
17. HENSRUD DD, JENSEN MD: Orlistat. Clin. Perspect. Gastroenterol (2000) 3(l):50-52. • Short review summarising clinical trials with orlistat.
18. HOLLANDER PA, ELBEIN SC, HIRSCH IB et al: Role of orlistat hi the treatment of obese patients with Type 2 diabetes. Diabetes Care (1998) 21:1288-1294.
19. NAGELE H, PETERSEN B, BONACKER U, RODIGER W: Effect of orlistat on blood cyclosporin concentration hi an obese heart transplant patient. Etir. J. Clin. Pbarmacol (1999) 55:667-669.